Sana Biotechnology (SANA) reported Tuesday "positive" initial results from a study that transplanted islet cells into a person with type 1 diabetes without the use of immunosuppression.
Sana shares were rising 225% in recent after-hours trading.
The study showed that the company's hypoimmune, or HIP, technology enabled the transplanted islet cells to avoid rejection and produce insulin without immunosuppression, the company said.
"Results of the study at four weeks after cell transplantation demonstrate the survival and function of pancreatic beta cells as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin," Sana said.
The study didn't identify any safety issues, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.